The median progression-free survival was @ months ( @ % confidence interval -LSB- CI -RSB- , @ to not estimable ) with palbociclib-fulvestrant and @ months ( @ % CI , @ to @ ) with placebo-fulvestrant ( hazard ratio for disease progression or death , @ ; @ % CI , @ to @ ; P < @ ) .